首页> 外文期刊>Nuclear Medicine Communications >Post-surgical ablation of thyroid remnants with high-dose (131)I in patients with differentiated thyroid carcinoma.
【24h】

Post-surgical ablation of thyroid remnants with high-dose (131)I in patients with differentiated thyroid carcinoma.

机译:分化型甲状腺癌患者的大剂量(131)I甲状腺残留手术后消融。

获取原文
获取原文并翻译 | 示例
           

摘要

The aims of this study were to evaluate the efficacy of an empirically determined "fixed" high ablative dose of radioiodine ((131)I) therapy and to determine the utility of ultrasonography (US) in dose determination. A retrospective analysis was performed of 242 thyroid cancer cases treated with "fixed" high-dose (131)I for ablation of thyroid remnants without a pre-ablative (131)I diagnostic scintigraphy or radioiodine uptake study. Treatment doses ranged from 1850 MBq (50 mCi) to 7.4 GBq (200 mCi). The selection of the treatment dose was based on the surgical and pathological findings as well as the remnant thyroid volume calculated by US. A successful ablation was defined as the absence of activity in the thyroid bed on subsequent imaging studies. Successful ablation was obtained in 218 of the 242 patients (90%). In 162 of the 218 patients (74.3%), successful ablation was achieved after a single (131)I treatment. The remnant thyroid volume calculated by US was significantly different (P=0.04) between those who were successfully ablated and those who were not. The total (131)I dose needed for successful ablation was significantly higher in males (P=0.003). Patients with higher post-operative thyroglobulin (Tgb) levels and patients with a higher stage of disease required higher doses (P=0.036 and P=0.021 respectively). Serum Tgb levels were under 10 ng.ml(-1) in 220 of the 242 patients (90%) following radioiodine ablation while not receiving L-thyroxine suppression. Nineteen patients (7.8%) showed metastases on post-therapy scan and successful treatment was achieved in 11 of 19 (57.8%). Four of the 19 patients with distant metastases (revealed on post-treatment scan) were found to have been given a treatment dose of less than 200 mCi based on the proposed empirical approach. These results indicate that "fixed" high-dose (131)I treatment is clinically feasible with an acceptable dose underestimation rate, and the utilization of US in the determination of the thyroid remnant volume provides more accurate and reproducible results.
机译:这项研究的目的是评估以经验确定的“固定”高烧蚀剂量放射性碘((131)I)治疗的疗效,并确定超声(US)在剂量确定中的效用。回顾性分析了242例接受“固定”高剂量(131)I治疗的甲状腺癌患者的甲状腺残留消融,但未进行消融前(131)I诊断闪烁显像或放射碘吸收研究。治疗剂量范围从1850 MBq(50 mCi)到7.4 GBq(200 mCi)。治疗剂量的选择基于手术和病理学发现以及US计算的甲状腺残留量。成功的消融定义为在随后的影像学研究中甲状腺床没有活动。 242例患者中有218例成功消融(90%)。在218名患者中的162名(74.3%)中,单次(131)I治疗后成功消融。通过US计算得出的残余甲状腺体积在成功消融者与未消融者之间有显着差异(P = 0.04)。成功消融所需的总(131)I剂量在男性中明显更高(P = 0.003)。术后甲状腺球蛋白(Tgb)水平较高的患者和疾病分期较高的患者需要更高的剂量(分别为P = 0.036和P = 0.021)。 242例患者中有220例(90%)的血清Tgb水平低于10 ng.ml(-1),但未接受L-甲状腺素抑制治疗。 19名患者(7.8%)在治疗后扫描中显示转移,并且19名患者中有11名(57.8%)获得了成功的治疗。根据拟议的经验方法,发现19例远处转移患者(在治疗后扫描中显示)中有4例的治疗剂量小于200 mCi。这些结果表明,“固定”高剂量(131)I治疗在临床上是可行的,并且可接受的剂量低估率也很高,并且US在测定甲状腺残余量中的利用提供了更准确和可重复的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号